<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Trandolapril</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00519</strong>&#160; (APRD01269)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (<span class="caps">ACE</span>) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits <span class="caps">ACE</span>, the enzyme responsible for the conversion of angiotensin I (<span class="caps">ATI</span>) to angiotensin II (<span class="caps">ATII</span>). <span class="caps">ATII</span> regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (<span class="caps">RAAS</span>). Trandolapril may be used to treat mild to moderate hypertension, to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, as an adjunct treatment for congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00519/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00519/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00519.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00519.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00519.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00519.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00519.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00519">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Trandolaprilum</td><td>Latin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Mavik</td><td>Abbott</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Tarka</td><td>trandolapril + verapamil hydrochloride</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/angiotensin-converting-enzyme-inhibitors">Angiotensin-Converting Enzyme Inhibitors</a></li>
<li><a href="/mesh/antihypertensive-agents">Antihypertensive Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>87679-37-6</td></tr><tr><th>Weight</th><td>Average: 430.5372<br>Monoisotopic: 430.246772208</td></tr><tr><th>Chemical Formula</th><td>C<sub>24</sub>H<sub>34</sub>N<sub>2</sub>O<sub>5</sub></td></tr><tr><th>InChI Key</th><td>VXFJYXUZANRPDJ-WTNASJBWSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C24H34N2O5/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29)/t16-,18+,19-,20-,21-/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(2S,3aR,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-octahydro-1H-indole-2-carboxylic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids and Derivatives</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Peptides</td></tr><tr><th>Alternative parents</th><td>N-acyl-alpha Amino Acids; Alpha Amino Acid Esters; Alpha Amino Acid Amides; Phenylpropylamines; Indoles and Derivatives; Pyrrolidine Carboxylic Acids; Fatty Acid Esters; Dicarboxylic Acids and Derivatives; Tertiary Carboxylic Acid Amides; Carboxylic Acid Esters; Tertiary Amines; Dialkylamines; Carboxylic Acids; Enolates; Ethers; Polyamines</td></tr><tr><th>Substituents</th><td>n-acyl-alpha amino acid or derivative; n-acyl-alpha-amino acid; alpha-amino acid ester; alpha-amino acid amide; alpha-amino acid or derivative; phenylpropylamine; indole or derivative; pyrrolidine carboxylic acid or derivative; pyrrolidine carboxylic acid; fatty acid ester; benzene; dicarboxylic acid derivative; pyrrolidine; tertiary carboxylic acid amide; tertiary amine; carboxamide group; carboxylic acid ester; polyamine; secondary amine; carboxylic acid; ether; enolate; secondary aliphatic amine; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure (CHF), to improve survival following myocardial infarction (MI) in individuals who are hemodynamically stable and demonstrate symptoms of left ventricular systolic dysfunction or signs of CHF within a few days following acute MI, and to slow progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy. </td></tr><tr><th>Pharmacodynamics</th><td>Trandolapril is the ethyl ester prodrug of a nonsulfhydryl ACE inhibitor, trandolaprilat. Trandolapril is deesterified in the liver to the diacid metabolite, trandolaprilat, which is approximately eight times more active as an inhibitor of ACE than its parent compound. ACE is a peptidyl dipeptidase that is part of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure via a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may further sustain the effects of trandolaprilat by causing increased vasodilation and decreased blood pressure. The blood pressure lowering effect of trandolaprilat is due to a decrease in peripheral vascular resistance, which is not accompanied by significant changes in urinary excretion of chloride or potassium or water or sodium retention. </td></tr><tr><th>Mechanism of action</th><td>There are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Trandolaprilat, the active metabolite of trandolapril, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Trandolaprilat also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors. </td></tr><tr><th>Absorption</th><td>~ 40-60% absorbed; extensive first pass metabolism results in a low bioavailability of 4-14%</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>18 L</li>
</ul></td></tr><tr><th>Protein binding</th><td>Serum protein binding of trandolapril is ~ 80% (independent of concentration and not saturable) while that of trandolaprilat is 65 to 94% (concentration-dependent and saturable).</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Cleavage of the ester group of trandolapril, primarily in the liver, is responsible for conversion to trandolaprilat, the active metabolite. Seven other metabolites, including diketopiperazine and glucuronide conjugated derivatives of trandolapril and trandolaprilat, have been identified. </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Trandolapril</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00840">Diketopiperazine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/861">Details</a></td></tr><tr><td>Trandolapril</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01014">Trandolaprilat</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1037">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>After oral administration of trandolapril, about 33% of parent drug and metabolites are recovered in urine, mostly as trandolaprilat, with about 66% in feces.</td></tr><tr><th>Half life</th><td>The elimination half lives of trandolapril and trandolaprilat are about 6 and 10 hours, respectively, but, similar to all ACE inhibitors, trandolaprilat also has a prolonged terminal elimination phase that involves a small fraction of administered drug. This likely represents drug binding to plasma and tissue ACE. The effective half life of elimination for trandolaprilat is 16-24 hours. </td></tr><tr><th>Clearance</th><td><ul>
	<li>52 L/h [After approximately 2 mg IV doses]</li>
</ul></td></tr><tr><th>Toxicity</th><td>Most likely clinical manifestations of overdose are symptoms of severe hypotension. Most common adverse effects include cough, headache and dizziness. The oral LD<sub>50</sub> of trandolapril in mice was 4875 mg/kg in males and 3990 mg/kg in females. In rats, an oral dose of 5000 mg/kg caused low mortality (1 male out of 5; 0 females). In dogs, an oral dose of 1000 mg/kg did not cause mortality and abnormal clinical signs were not observed.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Trandolapril Action Pathway</td><td>Drug action</td></tr><tr><td>Trandolapril Metabolism Pathway</td><td>Drug metabolism</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00599?highlight%5Bcompounds%5D%5B%5D=DB00519&amp;highlight%5Bproteins%5D%5B%5D=DB00519">SMP00599</a></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9303</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.8908</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.8501</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7744</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.5527</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.7759</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8336</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8227</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8935</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5515</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.915</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.785</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9018</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.796</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5339</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.6906</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9133
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9188
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9587
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.2048 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9811
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.5531
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Abbott laboratories pharmaceutical products div</li>
<li>Aurobindo pharma ltd</li>
<li>Cipla ltd</li>
<li>Corepharma llc</li>
<li>Dr reddys laboratories ltd</li>
<li>Epic pharma llc</li>
<li>Invagen pharmaceuticals inc</li>
<li>Lupin ltd</li>
<li>Mylan pharmaceuticals inc</li>
<li>Teva pharmaceuticals usa</li>
<li>Watson laboratories inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.abbott.com">Abbott Laboratories Ltd.</a></li>
<li>Arrow Pharm Malta Ltd.</li>
<li><a href="http://www.aurobindo.com">Aurobindo Pharma Ltd.</a></li>
<li><a href="http://BASF%20Corp.">BASF Corp.</a></li>
<li><a href="http://www.cipla.com">Cipla Ltd.</a></li>
<li><a href="http://www.cobaltpharma.com">Cobalt Pharmaceuticals Inc.</a></li>
<li><a href="http://www.corepharma.com">Corepharma LLC</a></li>
<li><a href="http://www.davapharma.com">DAVA Pharmaceuticals</a></li>
<li><a href="http://www.drreddys.com">Doctor Reddys Laboratories Ltd.</a></li>
<li><a href="http://www.glenmark-generics.com">Glenmark Generics Ltd.</a></li>
<li><a href="http://www.greenstonellc.com">Greenstone LLC</a></li>
<li><a href="http://www.invagen.com">InvaGen Pharmaceuticals Inc.</a></li>
<li><a href="http://www.lupinpharmaceuticals.com">Lupin Pharmaceuticals Inc.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.west-ward.com">West-Ward Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td>0.5 mg</td></tr><tr><td>Capsule</td><td>Oral</td><td>1 mg</td></tr><tr><td>Capsule</td><td>Oral</td><td>2 mg</td></tr><tr><td>Capsule</td><td>Oral</td><td>4 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00945">Acetylsalicylic acid</a></td><td>Acetylsalicylic acid may reduce the efficacy of Trandolapril. Monitor for changes in Trandolapril efficacy if Acetylsalicylic acid is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00437">Allopurinol</a></td><td>The ACE inhibitor, Trandolapril, may increase the risk of hypersensitivity reactions to Allopurinol. </td></tr><tr><td><a href="/drugs/DB01143">Amifostine</a></td><td>Trandolapril may increase the hypotensive effect of Amifostine. At chemotherapeutic doses of Amifostine, Trandolapril should be withheld for 24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine. </td></tr><tr><td><a href="/drugs/DB00594">Amiloride</a></td><td>Increased risk of hyperkalemia. Monitor serum potassium levels.</td></tr><tr><td><a href="/drugs/DB00233">Aminosalicylic Acid</a></td><td>The salicylate, Aminosalicylic acid, may reduce the efficacy of Trandolapril. Monitor for changes in Trandolapril efficacy if Aminosalicylic acid is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00993">Azathioprine</a></td><td>Trandolapril may increase the risk of neutropenia. Monitor for increased toxic effects of Azathioprine if Trandolapril is initiated or dose increased. </td></tr><tr><td><a href="/drugs/DB08822">Azilsartan medoxomil</a></td><td>Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.  </td></tr><tr><td><a href="/drugs/DB00436">Bendroflumethiazide</a></td><td>The thiazide diuretic, Bendroflumethiazide, may increase the hypotensive effect of Trandolapril. Bendroflumethiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. </td></tr><tr><td><a href="/drugs/DB00865">Benzphetamine</a></td><td>Benzphetamine may reduce the efficacy of Trandolapril. </td></tr><tr><td><a href="/drugs/DB00887">Bumetanide</a></td><td>The loop diuretic, Bumetanide, may increase the hypotensive effect of Trandolapril. Bumetanide may also increase the nephrotoxicity of Trandolapril. </td></tr><tr><td><a href="/drugs/DB00796">Candesartan</a></td><td>The angiotensin II receptor blocker, Candesartan, may increase the adverse effects of Trandolapril. </td></tr><tr><td><a href="/drugs/DB00482">Celecoxib</a></td><td>The NSAID, Celecoxib, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Celecoxib is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00880">Chlorothiazide</a></td><td>The thiazide diuretic, Chlorothiazide, may increase the hypotensive effect of Trandolapril. Chlorothiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. </td></tr><tr><td><a href="/drugs/DB00310">Chlorthalidone</a></td><td>The thiazide diuretic, Chlorthalidone, may increase the hypotensive effect of Trandolapril. Chlorthalidone may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. </td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>The ACE inhibitor, Trandolapril, may increase the nephrotoxicity of Cyclosporine. </td></tr><tr><td><a href="/drugs/DB01576">Dextroamphetamine</a></td><td>Dextroamphetamine may reduce the efficacy of Trandolapril. </td></tr><tr><td><a href="/drugs/DB01119">Diazoxide</a></td><td>Diazoxide may increase the hypotensive effect of Trandolapril. Monitor for changes in blood pressure.</td></tr><tr><td><a href="/drugs/DB00586">Diclofenac</a></td><td>The NSAID, Diclofenac, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Diclofenac is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00861">Diflunisal</a></td><td>The NSAID, Diflunisal, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Diflunisal is initiated, discontinued or dose changed.  </td></tr><tr><td><a href="/drugs/DB01395">Drospirenone</a></td><td>Increased risk of hyperkalemia. Monitor serum potassium levels. </td></tr><tr><td><a href="/drugs/DB01363">Ephedra</a></td><td>Ephedra may antagonize the antihypertensive effect of Trandolapril. Monitor Trandolapril efficacy.</td></tr><tr><td><a href="/drugs/DB00700">Eplerenone</a></td><td>Increased risk of hyperkalemia. Monitor serum potassium levels. </td></tr><tr><td><a href="/drugs/DB01240">Epoprostenol</a></td><td>The prostacyclin analogue, Epoprostenol, may increase the hypotensive effect of Trandolapril. </td></tr><tr><td><a href="/drugs/DB00876">Eprosartan</a></td><td>The angiotensin II receptor blocker, Eprosartan, may increase the adverse effects of Trandolapril. </td></tr><tr><td><a href="/drugs/DB00903">Ethacrynic acid</a></td><td>The loop diuretic, Ethacrynic acid, may increase the hypotensive effect of Trandolapril. Ethacrynic acid may also increase the nephrotoxicity of Trandolapril.  </td></tr><tr><td><a href="/drugs/DB00749">Etodolac</a></td><td>The NSAID, Etodolac, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Etodolac is initiated, discontinued or dose changed.  </td></tr><tr><td><a href="/drugs/DB00573">Fenoprofen</a></td><td>The NSAID, Fenoprofen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Fenoprofen is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00712">Flurbiprofen</a></td><td>The NSAID, Flurbiprofen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Flurbiprofen is initiated, discontinued or dose changed.  </td></tr><tr><td><a href="/drugs/DB00695">Furosemide</a></td><td>The loop diuretic, Furosemide, may increase the hypotensive effect of Trandolapril. Furosemide may also increase the nephrotoxicity of Trandolapril. </td></tr><tr><td><a href="/drugs/DB01404">Ginseng</a></td><td>Ginseng may antagonize the antihypertensive effect of Trandolapril. Monitor Trandolapril efficacy.</td></tr><tr><td><a href="/drugs/DB00999">Hydrochlorothiazide</a></td><td>The thiazide diuretic, Hydrochlorothiazide, may increase the hypotensive effect of Trandolapril. Hydrochlorothiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. </td></tr><tr><td><a href="/drugs/DB00774">Hydroflumethiazide</a></td><td>The thiazide diuretic, Hydroflumethiazide, may increase the hypotensive effect of Trandolapril. Hydroflumethiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. </td></tr><tr><td><a href="/drugs/DB01050">Ibuprofen</a></td><td>The NSAID, Ibuprofen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Ibuprofen is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB06196">Icatibant</a></td><td>Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01088">Iloprost</a></td><td>The prostacyclin analogue, Iloprost, may increase the hypotensive effect of Trandolapril.</td></tr><tr><td><a href="/drugs/DB00808">Indapamide</a></td><td>The thiazide diuretic, Indapamide, may increase the hypotensive effect of Trandolapril. Indapamide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. </td></tr><tr><td><a href="/drugs/DB00328">Indomethacin</a></td><td>The NSAID, Indomethacin, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Indomethacin is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB01029">Irbesartan</a></td><td>The angiotensin II receptor blocker, Irbesartan, may increase the adverse effects of Trandolapril. </td></tr><tr><td><a href="/drugs/DB01009">Ketoprofen</a></td><td>The NSAID, Ketoprofen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Ketoprofen is initiated, discontinued or dose changed.  </td></tr><tr><td><a href="/drugs/DB00465">Ketorolac</a></td><td>The NSAID, Ketorolac, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Ketorolac is initiated, discontinued or dose changed.  </td></tr><tr><td><a href="/drugs/DB01255">Lisdexamfetamine</a></td><td>Lisdexamfetamine may reduce the efficacy of Trandolapril. </td></tr><tr><td><a href="/drugs/DB01356">Lithium</a></td><td>Trandolapril may increase the serum concentration of Lithium increasing the risk of Lithium toxicity. Monitor for changes in Lithium serum concentrations, toxicity and efficacy if Trandolapril is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00678">Losartan</a></td><td>The angiotensin II receptor blocker, Losartan, may increase the adverse effects of Trandolapril. </td></tr><tr><td><a href="/drugs/DB01283">Lumiracoxib</a></td><td>The NSAID, Lumiracoxib, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Lumiracoxib is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00939">Meclofenamic acid</a></td><td>The NSAID, Meclofenamate, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Meclofenamate is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00784">Mefenamic acid</a></td><td>The NSAID, Mefenamic acid, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Mefenamic acid is initiated, discontinued or dose changed.  </td></tr><tr><td><a href="/drugs/DB00814">Meloxicam</a></td><td>The NSAID, Meloxicam, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Meloxicam is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB01577">Methamphetamine</a></td><td>Methamphetamine may reduce the efficacy of Trandolapril. </td></tr><tr><td><a href="/drugs/DB00232">Methyclothiazide</a></td><td>The thiazide diuretic, Methyclothiazide, may increase the hypotensive effect of Trandolapril. Methyclothiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. </td></tr><tr><td><a href="/drugs/DB00422">Methylphenidate</a></td><td>Methylphenidate may antagonize the antihypertensive effect of Trandolapril. Monitor for changes in blood pressure if Methylphenidate is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00524">Metolazone</a></td><td>The thiazide diuretic, Metolazone, may increase the hypotensive effect of Trandolapril. Metolazone may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. </td></tr><tr><td><a href="/drugs/DB00461">Nabumetone</a></td><td>The NSAID, Nabumetone, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Nabumetone is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00788">Naproxen</a></td><td>The NSAID, Naproxen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Naproxen is initiated, discontinued or dose changed.  </td></tr><tr><td><a href="/drugs/DB00275">Olmesartan</a></td><td>The angiotensin II receptor blocker, Olmesartan, may increase the adverse effects of Trandolapril. </td></tr><tr><td><a href="/drugs/DB00991">Oxaprozin</a></td><td>The NSAID, Oxaprozin, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Oxaprozin is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB01579">Phendimetrazine</a></td><td>Phendimetrazine may reduce the efficacy of Trandolapril. </td></tr><tr><td><a href="/drugs/DB00191">Phentermine</a></td><td>Phentermine may reduce the efficacy of Trandolapril. </td></tr><tr><td><a href="/drugs/DB00554">Piroxicam</a></td><td>The NSAID, Piroxicam, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Piroxicam is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB01324">Polythiazide</a></td><td>The thiazide diuretic, Polythiazide, may increase the hypotensive effect of Trandolapril. Polythiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. </td></tr><tr><td><a href="/drugs/DB01345">Potassium</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00761">Potassium Chloride</a></td><td>The potassium salt may increase the hyperkalemic effect of Trandolapril.</td></tr><tr><td><a href="/drugs/DB00468">Quinine</a></td><td>May cause additive hypotensive effects. Monitor for changes in blood pressure if Quinine is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00073">Rituximab</a></td><td>Trandolapril may incresae the hypotensive effect of Rituximab. </td></tr><tr><td><a href="/drugs/DB01399">Salsalate</a></td><td>The salicylate, Salsalate, may reduce the efficacy of Trandolapril. Monitor for changes in Trandolapril efficacy if Salsalate is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00877">Sirolimus</a></td><td>Increased risk of angioedema. Monitor for signs and symptoms of facial and systemic edema and/or erythema.</td></tr><tr><td><a href="/drugs/DB01390">Sodium bicarbonate</a></td><td>Sodium bicarbonate may decrease the absorption of Trandolapril. Administration should be spaced.</td></tr><tr><td><a href="/drugs/DB00421">Spironolactone</a></td><td>Increased risk of hyperkalemia. Monitor serum potassium levels. </td></tr><tr><td><a href="/drugs/DB00605">Sulindac</a></td><td>The NSAID, Sulindac, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Sulindac is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00966">Telmisartan</a></td><td>The angiotensin II receptor blocker, Telmisartan, may increase the adverse effects of Trandolapril. </td></tr><tr><td><a href="/drugs/DB06287">Temsirolimus</a></td><td>Increased risk of angioedema. Monitor for signs and symptoms of facial and systemic edema and/or erythema.</td></tr><tr><td><a href="/drugs/DB01600">Tiaprofenic acid</a></td><td>The NSAID, Tiaprofenic acid, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Tiaprofenic acid is initiated, discontinued or dose changed.  </td></tr><tr><td><a href="/drugs/DB00697">Tizanidine</a></td><td>Tizanidine increases the risk of hypotension with the ACE inhibitor</td></tr><tr><td><a href="/drugs/DB00500">Tolmetin</a></td><td>The NSAID, Tolmetin, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Tolmetin is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00214">Torasemide</a></td><td>The loop diuretic, Torasemide, may increase the hypotensive effect of Trandolapril. Torasemide may also increase the nephrotoxicity of Trandolapril. </td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>The prostacyclin analogue, Treprostinil, may increase the hypotensive effect of Trandolapril.</td></tr><tr><td><a href="/drugs/DB00384">Triamterene</a></td><td>Increased risk of hyperkalemia. Monitor serum potassium levels.</td></tr><tr><td><a href="/drugs/DB01021">Trichlormethiazide</a></td><td>The thiazide diuretic, Trichlormethiazide, may increase the hypotensive effect of Trandolapril. Trichlormethiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. </td></tr><tr><td><a href="/drugs/DB00440">Trimethoprim</a></td><td>Increased risk of hyperkalemia. Monitor serum potassium levels. </td></tr><tr><td><a href="/drugs/DB00177">Valsartan</a></td><td>The angiotensin II receptor blocker, Valsartan, may increase the adverse effects of Trandolapril. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Herbs that may attenuate the antihypertensive effect of trandolapril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.  </li>
<li>High salt intake may attenuate the antihypertensive effect of trandolapril. </li>
<li>Take without regard to meals.</li>
<li>Trandolapril may decrease the excretion of potassium. Salt substitutes containing potassium may increase the risk of hyperkalemia. </li></ul></td></tr></tbody></table>